Burt Wealth Advisors Sells 886 Shares of Pfizer Inc. (NYSE:PFE)

Burt Wealth Advisors decreased its position in Pfizer Inc. (NYSE:PFE) by 5.9% during the fourth quarter, Holdings Channel reports. The fund owned 14,045 shares of the biopharmaceutical company’s stock after selling 886 shares during the period. Burt Wealth Advisors’ holdings in Pfizer were worth $373,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Swedbank AB lifted its position in shares of Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after buying an additional 37,636 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Pfizer by 11.4% during the third quarter. Farther Finance Advisors LLC now owns 61,105 shares of the biopharmaceutical company’s stock valued at $1,768,000 after purchasing an additional 6,262 shares in the last quarter. Optas LLC boosted its position in shares of Pfizer by 5.8% in the third quarter. Optas LLC now owns 9,824 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 539 shares during the period. Harbor Capital Advisors Inc. raised its position in shares of Pfizer by 0.5% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 111,694 shares of the biopharmaceutical company’s stock valued at $3,232,000 after purchasing an additional 535 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its stake in shares of Pfizer by 120.7% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 4,498,313 shares of the biopharmaceutical company’s stock valued at $130,181,000 after buying an additional 2,459,666 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.8 %

Shares of PFE opened at $26.21 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a fifty day moving average of $26.34 and a 200 day moving average of $27.30. The company has a market cap of $148.53 billion, a PE ratio of 18.59, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.56%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Analyst Ratings Changes

A number of equities research analysts have commented on PFE shares. Guggenheim reissued a “buy” rating and set a $33.00 price target on shares of Pfizer in a report on Monday, February 10th. Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.